A virus antigen detection kit and its application

A fusion protein-based detection kit for rotavirus VP8 protein is developed, offering high immunogenicity and accurate quantification, addressing the lack of detection methods for this critical vaccine target.

CN115873131BActive Publication Date: 2024-12-06SHENZHEN HUIAN BIOSCITECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211594528.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-12-13
Publication Date
2024-12-06
Estimated Expiration
2042-12-13

AI Technical Summary

Technical Problem

There is currently no detection kit available for the rotavirus VP8 protein, which is a key target for subunit vaccine research, and existing technologies lack effective methods for detecting and quantifying this protein.

Method used

A fusion protein is developed, comprising specific amino acid sequences that bind to MHC class I and II molecules, rotavirus VP8 protein antigen polypeptides, a linker, and a B cell antigen epitope, along with a tag, which is used to create a vaccine and a detection kit utilizing monoclonal antibodies for accurate detection and quantification of VP8 protein.

Benefits of technology

The fusion protein exhibits high immunogenicity and antibody titers, and the detection kit effectively detects and measures the concentration of the rotavirus VP8 protein, providing a sensitive and accurate method for quantifying the protein.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115873131B_ABST
    Figure CN115873131B_ABST
Patent Text Reader

Abstract

The present invention discloses a rotavirus fusion protein and the nucleotide sequence of the fusion protein after codon optimization, and the sequence is shown in SEQ ID NO.1. The present invention also discloses a rotavirus vaccine prepared using the fusion protein. The fusion protein disclosed in the present invention has good immunogenicity and can produce higher antibody titers than conventional rotavirus VP8 proteins, providing an important reference for the research and development of rotavirus subunit vaccines. In addition, the present invention discloses a kit for quantitatively detecting the fusion protein, the kit comprising an effective amount of the fusion protein and an effective amount of a monoclonal antibody that specifically binds to the fusion protein and a matching detection reagent. The kit has high sensitivity and accuracy, and can accurately detect not only the concentration of the prepared fusion protein, but also the concentration of the rotavirus VP8 protein.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and specifically relates to a virus antigen detection kit and application thereof. Background Art

[0002] Rotavirus (RV) is a double-stranded RNA virus belonging to the Reoviridae family. It is the single leading cause of diarrhea in infants and young children. Almost every child in the world around the age of five has been infected with rotavirus at least once. There are seven types of rotavirus, numbered alphabetically as A, B, C, D, E, F and G. Type A is the most common type, and more than 90% of human rotavirus infections are caused by this type.

[0003] Rotavirus is transmitted via the fecal-oral route. It infects the enterocytes that line the small intestine and produces enterotoxins, which cause gastroenteritis, severe diarrhea, and sometimes death from dehydration. Although rotavirus was discovered in 1973 by Ruth Bishop of Australia and is responsible for more than 50% of hospitalizations for severe diarrhea in infants and young children, it is still not widely recognized in the public health community, especially in developing countries. In addition to its impact on human health, rotavirus can also infect animals and is a pathogen of livestock.

[0004] The rotavirus genome consists of 11 unique RNA double helices with a total of 18,555 nucleotide base pairs. Each helix or segment is a gene and is numbered from 1 to 11 in descending order of molecular size. Each gene can encode a protein, but genes 9 and 11 are special in that they can encode two proteins. The RNA is surrounded by a three-layer icosahedral protein shell. The virus particle is approximately 76.5nm in diameter and does not have a viral envelope. There are six viral proteins (VP) that structure the entire virus particle (virion). These "structural" proteins are called VP1, VP2, VP3, VP4, VP6 and VP7. In addition to these structural proteins, there are six nonstructural proteins (NSP), which are only produced in rotavirus-infected cells and do not constitute the structure of the virion. These six non-structural proteins are called NSP1, NSP2, NSP3, NSP4, NSP5 and NSP6.

[0005] The VP4 protein is located on the surface of the virus body, protruding into a spike. It connects to receptor molecules on the cell surface and drives the virus into the cell. Before the virus becomes contagious, the VP4 protein is changed into VP5* protein and VP8* protein by a protease that can be found in the internal organs. The VP4 protein determines the toxicity of the virus, and it also determines the P type of the virus. Chinese invention patent (CN 108546288 B)

[009] paragraph points out that VP8 protein is the main target protein for rotavirus subunit vaccine research. However, there is currently no detection kit for VP8 protein on the market. Therefore, it is necessary to develop a detection kit for rotavirus VP8 protein. Summary of the invention

[0006] In order to make up for the shortcomings of the prior art, one of the purposes of the present invention is to provide a rotavirus fusion protein and its monoclonal antibody and preparation method; the second purpose of the present invention is to provide a vaccine prepared using the fusion protein prepared by the present invention; the third purpose of the present invention is to provide a kit for detecting rotavirus VP8 protein using the monoclonal antibody and fusion protein prepared by the present invention.

[0007] In one aspect, the present invention provides a fusion protein, wherein the fusion protein is a rotavirus fusion protein, and the amino acid sequence of the fusion protein is:

[0008] NKKDKNPKDGGSQVDGYFIGLGGSAQTRYAPVNWGHGEINDSTTGGSIFGES

[0009] KQFNVSNDSNKWKFLGGSEMFRSSSQNEFYNRRTLTSDGGSTRFVGILKYGG RVWTFHGETGGSPENLDQKNKDETQQKQGGSHHHHHH.

[0010] Preferably, the codon-optimized nucleotide sequence encoding the fusion protein of the present invention is as shown in SEQ ID NO.1.

[0011] Preferably, the fusion protein of the present invention comprises a polypeptide that can bind to MHC class II molecules and MHC class I molecules, a rotavirus VP8 protein antigen polypeptide, a linker, a B cell antigen epitope and a tag.

[0012] Preferably, the amino acid sequences of the polypeptides capable of binding to MHC class II molecules and MHC class I molecules according to the present invention are respectively:

[0013] The amino acid sequence that can bind to MHC class II molecules is: NKKDKNPKD;

[0014] The amino acid sequence that can bind to MHC class I molecules is: QVDGYFIGL.

[0015] Preferably, the rotavirus VP8 protein antigen polypeptide of the present invention is composed of four rotavirus VP8 protein antigen polypeptides, and the amino acid sequences of the four rotavirus VP8 protein antigen polypeptides are respectively:

[0016] Antigenic peptide 2: AQTRYAPVNWGHGEINDSTT;

[0017] Antigenic peptide 6: IFGESKQFNVSNDSNKWKFL;

[0018] Antigenic peptide 7: EMFRSSSQNEFYNRRTLTSD;

[0019] Antigenic peptide 8: TRFVGILKYGGRVWTFHGET.

[0020] Preferably, the amino acid sequence of the linker described in the present invention is: GGS.

[0021] Preferably, the amino acid sequence of the B cell antigen epitope described in the present invention is: PENLDQKNKDETQQKQ.

[0022] Preferably, the tag described in the present invention is 6 His tags.

[0023] In another aspect, the present invention also provides a rotavirus vaccine, wherein the vaccine contains an effective amount of the fusion protein.

[0024] In yet another aspect, the present invention further provides a kit for quantitatively detecting the fusion protein, the kit comprising an effective amount of the fusion protein and an effective amount of a monoclonal antibody that specifically binds to the fusion protein and a matching detection reagent; the monoclonal antibodies that specifically bind to the fusion protein are monoclonal antibody 2 and monoclonal antibody 7; the sequences encoding the heavy chain variable region and the light chain variable region of monoclonal antibody 2 are shown in SEQ ID NO.2 and SEQ ID NO.3; the sequences encoding the heavy chain variable region and the light chain variable region of monoclonal antibody 7 are shown in SEQ ID NO.4 and SEQ ID NO.5.

[0025] Based on the rotavirus VP8 protein, the present invention obtains a fusion protein targeting the rotavirus VP8 protein through analysis and screening. The fusion protein has good immunogenicity and can produce higher antibody titers than conventional rotavirus VP8 proteins, providing an important reference for the research and development of rotavirus subunit vaccines.

[0026] The four polypeptides of rotavirus VP8 protein screened by the present invention have good antigenicity, which provides an important reference for the research of rotavirus VP8 protein and also provides important antigen clues for the subsequent development of monoclonal antibodies of rotavirus VP8 protein.

[0027] The present invention screened two specific monoclonal antibodies based on rotavirus VP8 protein antigenic polypeptide 2 and antigenic polypeptide 7, providing a good tool for establishing the detection of fusion protein. Both of these monoclonal antibodies have good specificity. Therefore, these two monoclonal antibodies are not only suitable for the detection of the fusion protein of the present invention, but also suitable for the detection of rotavirus VP8 protein.

[0028] Based on the fusion protein and monoclonal antibody studied in the present invention, a kit for detecting the fusion protein of the present invention is developed, which has high sensitivity and accuracy, and can not only accurately detect the concentration of the prepared fusion protein, but also the concentration of the rotavirus VP8 protein. Therefore, the kit has good applicability. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 Analysis results of the disordered region of rotavirus VP8 protein. The higher the score, the greater the probability that the position is a disordered region, and 0.5 is used as the dividing line for whether it is a disordered region.

[0030] Figure 2 Fusion protein SDS-PAGE detection results, where 1 is the fusion protein.

[0031] Figure 3 SDS-PAGE detection diagram of two monoclonal antibodies, 1 is monoclonal antibody 2, and 2 is monoclonal antibody 7.

[0032] Figure 4 Kit standard curve. DETAILED DESCRIPTION

[0033] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used herein includes any and all combinations of one or more related listed items.

[0034] Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art. Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0035] Example 1: Design and preparation of rotavirus fusion protein

[0036] The inventors selected the VP8 protein in the rotavirus VP4 protein as the key research target protein, and selected the N-terminal 1-230 amino acids (this segment is the VP8 protein) sequence in the rotavirus VP4 protein (P11193·VP4_ROTHW) for analysis and optimization screening of antigenic polypeptides.

[0037] The amino acid sequence of VP8 protein is:

[0038] MASLIYRQLLTNSYSVDLHDEIEQIGSEKTQNVTINPSPFAQTRYAPVNWGHG

[0039] EINDSTTVEPILDGPYQPTTFTPPNDYWILINSNTNGVVYESTNNSDFWTAVVA

[0040] IEPHVNPVDRQYTIFGESKQFNVSNDSNKWKFLEMFRSSSQNEFYNRRTLTSD

[0041] TRFVGILKYGGRVWTFHGETPRATTDSSSTANLNNISITIHSEFYIIPRSQESKCNEYINNGLPPIQNTR.

[0042] By analyzing the disordered region of the amino acid sequence of VP8 protein ( Figure 1 ), among which aa20-40, 60-70, 180-190, and 210-230 were predicted to be disordered regions. Therefore, when designing peptides, we avoided this region. The specific peptides are shown in Table 1.

[0043] Table 1 Antigen peptide design

[0044]

[0045]

[0046] The 9 antigenic peptides were used to immunize mice, and the mouse serum was collected for ELISA antibody titer detection to screen the antigenic epitope peptide with the highest antibody titer. After testing, the antibody titers of antigenic peptides 2, 6, 7, and 8 were the highest (Table 1), so these 4 antigenic peptides were selected as the focus of subsequent research.

[0047] ELISA antibody titer detection: VP8 protein was prepared using a conventional method for expressing exogenous proteins (see the preparation of recombinant VP8 protein without exogenous polypeptides described in Example 108546288B), coated on an ELISA plate, 100 ng / well, 0.1 ml / well, coated overnight at 4°C; after washing 3 times, blocked with 5% skim milk, incubated at 37°C for 2 h; mouse serum was serially diluted 10-fold with PBS (10-10 7 ), then added to the coated ELISA plate, 0.1 ml / well, incubated at 37°C for 1 hour; after washing 3 times, added 1:5000 diluted HRP-labeled goat anti-mouse IgG secondary antibody, 0.1 ml / well, incubated at 37°C for 30 minutes; after washing 3 times, added 0.1 ml TMB colorimetric solution, incubated at 37°C for 10 minutes; added stop solution (2 M sulfuric acid), and measured OD450nm value; when the sample OD450nm value / blank control OD450nm value was greater than 2.1 and the sample OD450nm value was greater than 0.1, it was judged to be positive.

[0048] The four antigen polypeptides were combined into a fusion protein. The two polypeptides were connected by "GGS", and two amino acid sequences (NKKDKNPKD, which can bind to MHC class II molecules; QVDGYFIGL, which can bind to MHC class I molecules) were added to the N-terminus. An amino acid sequence (PENLDQKNKDETQQKQ, one of the B cell antigen epitopes) and 6 His tags were added to the C-terminus to form a complete fusion protein. The full length of the fusion protein is 141 amino acids. The specific amino acid sequence is as follows:

[0049] NKKDKNPKDGGSQVDGYFIGLGGSAQTRYAPVNWGHGEINDSTTGGSIFGES

[0050] KQFNVSNDSNKWKFLGGSEMFRSSSQNEFYNRRTLTSDGGSTRFVGILKYGG RVWTFHGETGGSPENLDQKNKDETQQKQGGSHHHHHH.

[0051] The fusion protein sequence was codon optimized and fully synthesized in E. coli; the synthesized gene was connected to the pET28a vector, and the synthesized gene sequence was shown in SEQ ID NO.1. The recombinant plasmid was transformed into the E. coli BL21 (DE3) host, and after resistance screening and recombinant plasmid identification, the strain was preserved as an engineered bacterium expressing the recombinant protein. The fusion protein was prepared according to the conventional prokaryotic expression method, and the prepared fusion protein was stored below -70°C for future use.

[0052] The fusion protein was tested by SDS-PAGE protein gel electrophoresis, and there was a clear band at around 15KD, with a purity greater than 95% ( Figure 2 ); BCA was used to detect the protein concentration, and the fusion protein concentration was 0.89 mg / ml.

[0053] Example 2: Preparation and testing of rotavirus vaccine

[0054] The fusion protein prepared in Example 1 was diluted to 100 μg / ml, and the vaccine was prepared by emulsification with ISA201VG adjuvant (purchased from France Cepic Company) at a mass ratio of 1:1, and the concentration of the fusion protein in the vaccine was about 50 μg / ml. The VP8 protein prepared in Example 1 was used to prepare a vaccine in the same manner. The prepared vaccine was used to immunize 6-week-old female Balb / c mice, 5 mice per group. The specific vaccine information and immunization design are shown in Table 2.

[0055] Table 2 Vaccine information and immunization

[0056]

[0057] After immunization, the antibody titer after immunization was detected by indirect ELISA method. The results are shown in Table 3. It can be seen from the results that vaccine 1 has a better immune effect and a higher antibody titer than vaccine 2. This shows that the fusion protein prepared by the present invention has a good immune effect and is better than the recombinant VP8 protein.

[0058] Table 3 Antibody titer tracking results after immunization

[0059]

[0060] The indirect ELISA method for detecting antibody titer is briefly described as follows: the VP8 protein prepared in Example 1 is used to coat the ELISA plate (1 μg / ml, coated overnight at 4°C), and after blocking with PBST containing 1% BSA (incubated at 37°C for 2h), the ELISA plate is temporarily stored at 4°C for use; mouse serum is serially diluted with PBS (such as 50, 100, 200, 400, 800, 1600, 3200, 6400, 12800, 25600, 51200, 102400, etc.), and then added to the coated enzyme plate. In the labeled plate, 0.1 ml / well, incubate at 37°C for 1 hour; after washing, add 1:5000 diluted HRP-labeled goat anti-mouse IgG secondary antibody, 0.1 ml / well, incubate at 37°C for 30 minutes; after washing, add 0.1 ml of color development solution, incubate at 37°C for 10 minutes; add stop solution (2M sulfuric acid) and measure OD450nm value; when the P / N value (sample OD450nm value / blank control well OD450nm value) is greater than 2.1 and the sample ODOD450nm value is greater than 0.1, it is judged to be positive.

[0061] Example 3: Preparation and testing of anti-rotavirus polypeptide monoclonal antibodies

[0062] Considering the pairing problem of monoclonal antibodies, antigenic peptide 2 and antigenic peptide 7 with relatively high titers were selected as immunogens, and the two antigenic peptides were emulsified with adjuvants to prepare vaccines (100ng / ml), immunized mice, and monoclonal antibodies were prepared using conventional hybridoma cell technology. The specific methods are briefly described as follows:

[0063] Female BALB / c mice aged 6 to 8 weeks were selected and immunized according to the established immunization scheme (two antigen polypeptides were fully emulsified with equal weight of Freund's complete adjuvant and injected into the dorsal abdomen of mice at multiple points, 0.2 ml / mouse; 2 weeks later, an equal amount of antigen and an equal weight of Freund's incomplete adjuvant were taken and fully emulsified, and then 0.2 ml / mouse was injected intraperitoneally for the second time, and a double dose of antigen was used for intraperitoneal immunization after 2 weeks). After three immunizations, mouse spleen cells were separated and fused with myeloma cells Sp2 / 0, and then cloned by limiting dilution method, and the cell lines with high antibody titer and good morphology were screened and subcloned by limiting dilution method until monoclonal cells were obtained, and the monoclonal cells were expanded and cultured and stored in liquid nitrogen. After multiple rounds of testing and screening, two good hybridoma cells were obtained, named hybridoma cell 2 (obtained from antigenic polypeptide 2) and hybridoma cell 7 (obtained from antigenic polypeptide 7). Based on the hybridoma cells, two monoclonal antibodies were obtained by ascites preparation and antibody purification. 20 μl of the purified antibodies were taken and tested for purity using SDS-PAGE. The results showed that ( Figure 3 ), the SDS-PAGE purity of the two monoclonal antibodies was greater than 95%; the protein concentration of the purified antibodies was detected using a BCA kit, and the concentrations of monoclonal antibody 2 and monoclonal antibody 7 were 2.25 mg / ml and 2.18 mg / ml, respectively.

[0064] The heavy chain variable region and light chain variable region of the prepared monoclonal antibodies were analyzed and determined. After detection and analysis, the heavy chain variable region and light chain variable region sequences encoding monoclonal antibody 2 are shown in SEQ ID NO.2 and SEQ ID NO.3, respectively; the heavy chain variable region and light chain variable region sequences encoding monoclonal antibody 7 are shown in SEQ ID NO.4 and SEQ ID NO.5, respectively.

[0065] Example 4: Detection of fusion protein content

[0066] It can be seen from the results of Example 2 that the fusion protein prepared by the present invention has a good immune effect. However, in the process of preparing the fusion protein, the quantification of the fusion protein is an issue that needs to be focused on and resolved. To this end, the inventors developed an antigen detection kit based on the monoclonal antibody prepared in Example 3.

[0067] The preparation and detection of the kit are as follows:

[0068] 4.1 Preparation of Calibrators

[0069] The fusion protein prepared in Example 1 was used as a mother solution, and diluted with a diluent (TBST buffer containing 2% BSA) to prepare the calibrator. The concentration of the calibrator was:

[0070] 3000, 500, 100, 25, 5.0, 2.5, 0.0ng / ml.

[0071] 4.2 The magnetic particles were coupled to the monoclonal antibody 2 in a conventional EDC-activated carboxyl manner. The specific process is briefly described as follows:

[0072] 1) Take 1 mg of carboxyl magnetic particles (purchased from ThermoFisher), wash them three times with 0.1 M MES buffer and resuspend them in 0.5 ml MES (pH 6.0) buffer.

[0073] 2) Add 10 μg of monoclonal antibody 2, mix well, and incubate at room temperature for 20 min.

[0074] 3) Add 10 μl EDC (10 mg / ml), mix well, and incubate at room temperature for 2 h.

[0075] 4) After centrifugation, discard the supernatant, add 500 μl of washing buffer (TBST), and wash three times.

[0076] 5) Block with TBST buffer containing 1% BSA at room temperature for 2 h.

[0077] 6) After washing three times with TBST, resuspend with 0.5 ml of TBST buffer containing 1% BSA and store at 2-8°C until use.

[0078] 4.3 Alkaline phosphatase (AP) labeling of monoclonal antibody 7 is a conventional labeling method, and the specific process is briefly described as follows:

[0079] 1) Dissolve 5 mg AP in 1 ml monoclonal antibody 7 solution (2 mg / ml), put it into a dialysis bag, and dialyze it against 0.01 mol / L pH 7.2 PBS at 4°C for 18 hours, changing the solution three times.

[0080] 2) Add 20 μl of 2.5% glutaraldehyde and incubate at room temperature for 1-2 hours. Dialyze against PBS at 4°C overnight, changing the solution three times.

[0081] 3) The cell was dialyzed with 0.05 mol / L PH8.0 Tris-HCl buffer at 4°C overnight, with the buffer changed three times.

[0082] 4) Take out the labeled antibody and dilute it to 4 ml with Tris-HCl buffer containing 1% BSA, which is the AP marker stock solution.

[0083] 5) Add 0.4 ml of glycerol per ml, divide into small portions (e.g. 0.5 ml / tube), and store at 2-8°C for later use.

[0084] 4.4 Kit detection

[0085] 4.4.1 Preparation of detection kit

[0086] Dilute the magnetic particles coupled to monoclonal antibody 2 in 4.2 to 0.2 mg / ml and label it as reagent R1;

[0087] Dilute the monoclonal antibody 7 labeled with alkaline phosphatase in 4.3 by 500 times and label it as reagent R2;

[0088] The diluent was 0.1% BSA TBS pH 7.4.

[0089] 4.4.2 Detection steps

[0090] 1) 10 μl sample + 50 μl reagent R1 + 50 μl reagent R2 + 90 μl wash buffer;

[0091] 2) Incubate with mixing at 37°C for 15 min (37°C 1000 rpm);

[0092] 3) Wash with wash buffer 3 times, 500 μl each time;

[0093] 4) Add 200 μl of substrate (alkaline phosphatase colorimetric substrate purchased from Beckman or other manufacturers) and immediately detect the RLU value using a chemiluminescence instrument.

[0094] The wash buffer is TBST buffer.

[0095] 4.5 Kit performance evaluation

[0096] 4.5.1 Kit sensitivity

[0097] First, use the calibration material for calibration (the calibration curve is as follows Figure 4As shown), then 0.9% NaCl was used as a blank sample, and the blank sample was tested 20 times. The average value of the blank sample plus 3 times the standard deviation was taken as the detection limit of this kit. After testing and calculation, the detection limit of this kit is 0.5ng / ml.

[0098] 4.5.2 Sample testing:

[0099] The fusion protein and recombinant protein prepared in Example 1 were tested and compared with the BCA test results (converted according to SDS-PAGE purity). The results showed that the results of the test kit were basically consistent with those of BCA, with a deviation of about 5%. See Table 4 for details.

[0100] Table 4 Test results of the kit

[0101]

[0102] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. A fusion protein, wherein the fusion protein is a rotavirus fusion protein, It is characterized in that The amino acid sequence of the fusion protein is: NKKDKNPKDGGSQVDGYFIGLGGSAQTRYAPVNWGHGEINDSTTGGSIFGESKQFNVSNDSNKWKFLGGSEMFRSSSQNEFYNRRTLTSDGGSTRFVGILKYGGRVWTFHGETGGSPENLDQKNKDETQQKQGGSHHHHHH.

2. A nucleic acid encoding the fusion protein according to claim 1, It is characterized in that The codon-optimized nucleotide sequence encoding the fusion protein is shown in SEQ ID NO.

1.

3. A kit for quantitatively detecting the fusion protein according to claim 1, It is characterized in that The kit comprises an effective amount of the fusion protein of claim 1, an effective amount of a monoclonal antibody that specifically binds to the fusion protein of claim 1, and a matching detection reagent; the monoclonal antibodies that specifically bind to the fusion protein of claim 1 are monoclonal antibody 2 and monoclonal antibody 7; the sequences encoding the heavy chain variable region and the light chain variable region of monoclonal antibody 2 are shown in SEQ ID NO.2 and SEQ ID NO.3; the sequences encoding the heavy chain variable region and the light chain variable region of monoclonal antibody 7 are shown in SEQ ID NO.4 and SEQ ID NO.5.